Stonebridge Capital Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,173
| Closed | -$115K | – | 464 |
|
|
2023
Q3 | $115K | Sell |
3,173
-332
| -9% | -$11.8K | 0.01% | 257 |
|
|
2023
Q2 | $125K | Sell |
3,505
-257
| -7% | -$9.22K | 0.01% | 245 |
|
|
2023
Q1 | $134K | Sell |
3,762
-2,854
| -43% | -$99.8K | 0.02% | 239 |
|
|
2022
Q4 | $232K | Sell |
6,616
-660
| -9% | -$22K | 0.03% | 189 |
|
|
2022
Q3 | $214K | Sell |
7,276
-1,120
| -13% | -$42.4K | 0.03% | 183 |
|
|
2022
Q2 | $457K | Sell |
8,396
-2,126
| -20% | -$117K | 0.06% | 137 |
|
|
2022
Q1 | $573K | Sell |
10,522
-23,116
| -69% | -$1.26M | 0.06% | 132 |
|
|
2021
Q4 | $1.85M | Buy |
33,638
+1,676
| +5% | +$87.2K | 0.2% | 99 |
|
|
2021
Q3 | $1.53M | Sell |
31,962
-31,881
| -50% | -$1.6M | 0.19% | 103 |
|
|
2021
Q2 | $3.02M | Buy |
63,843
+32,771
| +105% | +$1.57M | 0.19% | 102 |
|
|
2021
Q1 | $1.39M | Buy |
31,072
+1,544
| +5% | +$70.1K | 0.18% | 102 |
|
|
2020
Q4 | $1.36M | Buy |
29,528
+3,180
| +12% | +$146K | 0.21% | 99 |
|
|
2020
Q3 | $1.24M | Sell |
26,348
-352
| -1% | -$17.6K | 0.22% | 94 |
|
|
2020
Q2 | $1.36M | Sell |
26,700
-395
| -1% | -$20.3K | 0.25% | 92 |
|
|
2020
Q1 | $1.28M | Buy |
27,095
+2,348
| +9% | +$125K | 0.27% | 89 |
|
|
2019
Q4 | $1.45M | Buy |
24,747
+997
| +4% | +$55.5K | 0.24% | 92 |
|
|
2019
Q3 | $1.27M | Buy |
23,750
+576
| +2% | +$29.6K | 0.22% | 97 |
|
|
2019
Q2 | $1.16M | Buy |
23,174
+1,612
| +7% | +$80.9K | 0.21% | 98 |
|
|
2019
Q1 | $1.13M | Buy |
21,562
+821
| +4% | +$41K | 0.21% | 106 |
|
|
2018
Q4 | $991K | Buy |
20,741
+1,360
| +7% | +$67K | 0.23% | 91 |
|
|
2018
Q3 | $973K | Sell |
19,381
-782
| -4% | -$39.7K | 0.2% | 98 |
|
|
2018
Q2 | $1.02M | Buy |
20,163
+1,436
| +8% | +$72.3K | 0.22% | 93 |
|
|
2018
Q1 | $915K | Buy |
18,727
+675
| +4% | +$31.4K | 0.21% | 96 |
|
|
2017
Q4 | $800K | Buy |
18,052
+458
| +3% | +$21.2K | 0.18% | 103 |
|
|
2017
Q3 | $893K | Buy |
17,594
+883
| +5% | +$44.8K | 0.22% | 97 |
|
|
2017
Q2 | $901K | Buy |
16,711
+2,632
| +19% | +$140K | 0.24% | 95 |
|
|
2017
Q1 | $742K | Buy |
14,079
+580
| +4% | +$29.4K | 0.2% | 100 |
|
|
2016
Q4 | $650K | Buy |
13,499
+122
| +0.9% | +$6.03K | 0.19% | 101 |
|
|
2016
Q3 | $721K | Buy |
13,377
+2,293
| +21% | +$126K | 0.23% | 100 |
|
|
2016
Q2 | $600K | Buy |
11,084
+722
| +7% | +$38K | 0.2% | 102 |
|
|
2016
Q1 | $525K | Sell |
10,362
-22
| -0.2% | -$1.1K | 0.19% | 105 |
|
|
2015
Q4 | $524K | Sell |
10,384
-876
| -8% | -$44.7K | 0.19% | 105 |
|
|
2015
Q3 | $541K | Buy |
11,260
+475
| +4% | +$24.7K | 0.22% | 103 |
|
|
2015
Q2 | $561K | Buy |
10,785
+1,184
| +12% | +$66.7K | 0.22% | 102 |
|
|
2015
Q1 | $554K | Buy |
9,601
+1,261
| +15% | +$72.3K | 0.21% | 105 |
|
|
2014
Q4 | $446K | Buy |
8,340
+1,768
| +27% | +$98.9K | 0.18% | 110 |
|
|
2014
Q3 | $378K | Buy |
6,572
+2,672
| +69% | +$164K | 0.17% | 111 |
|
|
2014
Q2 | $261K | Buy |
+3,900
| New | +$264K | 0.12% | 123 |
|
Other funds holding GSK
JEST
Stonebridge Capital Advisors's GSK Position: Q4 2023 in Review
Stonebridge Capital Advisors sold out of GSK (GSK) in Q4 2023, closing a stake of 3,173 shares — an estimated $115K sold.
Stonebridge Capital Advisors first reported a position in GSK in Q2 2014 and held it in 38 quarters. The position peaked at $3.02M in Q2 2021. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.
- Stonebridge Capital Advisors reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
- Stonebridge Capital Advisors sold 3,173 GSK shares in Q4 2023, an estimated $115K.
- Stonebridge Capital Advisors first reported a position in GSK in Q2 2014 and held it in 38 quarters.
- Stonebridge Capital Advisors's GSK position peaked at $3.02M in Q2 2021.
- 895 funds tracked by Wall St. Rank held GSK as of Q4 2023.
Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.